Zealand Pharma Shares Outstanding 2017-2021 | ZEAL

Zealand Pharma shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Zealand Pharma Annual Shares Outstanding
(Millions of Shares)
2020 38
2019 34
2018 31
2017 28
2016 24
Zealand Pharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 43
2021-03-31 42
2020-12-31 38
2020-09-30 40
2020-06-30 37
2020-03-31 36
2019-12-31 34
2019-09-30 33
2019-06-30 32
2019-03-31 31
2018-12-31 31
2018-09-30 31
2018-06-30 31
2018-03-31 31
2017-12-31 28
2017-09-30 28
2017-06-30 26
2017-03-31 26
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.426B $0.054B
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29